Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorChinese PLA General Hospital
About this trial
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
Must have undergone bronchoalveolar lavage.
Age≥18 years old.
Disqualifiers
Patients who had other connective tissue diseases.
Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
Pregnant or lactating patients.
The patient also participated in any other clinical trial.
Trial population
Anti-MDA5 antibody positive dermatomyositis patients with or without interstitial lung disease
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The relationship between the microbial community and the presence or absence of interstitial lung disease
The relationship between the microbial community and the presence or absence of interstitial lung disease
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov